Every pharmaceutical-grade medicine begins with the right genetics. Stable cultivars form the biological foundation for reliable cannabinoid medicines.
At Curity Pharma, genetics are more than the starting point of cultivation. They are the foundation upon which pharmaceutical quality is built.
Why genetics matter
Consistency starts before cultivation.
Every Cannabis sativa cultivar possesses a unique genetic blueprint that determines its morphology, growth characteristics and the biosynthesis of naturally occurring cannabinoids, terpenes and other phytochemicals. These inherited traits influence not only how a plant develops, but also the consistency and reproducibility of the botanical raw material used throughout pharmaceutical manufacturing.
Unlike many agricultural crops, medicinal cannabis must deliver reproducible quality from one production cycle to the next. Achieving this begins with selecting cultivars capable of expressing stable genetic, morphological and phytochemical characteristics under carefully controlled cultivation conditions.
While environmental factors, cultivation practices and manufacturing processes all influence the final medicinal product, genetics provide the biological framework upon which these processes are built.
From genetics to medicine
A controlled path from plant to patient.
Each stage of production builds upon the previous one, creating a fully integrated process designed to preserve quality, consistency and traceability.
By maintaining control throughout this process, Curity Pharma is able to continuously monitor quality, optimise production and ensure that every stage contributes to the consistency of the final medicinal product.
Our philosophy
Selection for pharmaceutical production is different.
Selecting genetics for pharmaceutical production requires a fundamentally different approach from traditional cultivation.
Our objective is not simply to identify cultivars with desirable cannabinoid concentrations or distinctive terpene profiles. Instead, we evaluate genetics based on their ability to support reliable pharmaceutical manufacturing through consistent performance, predictable phytochemical expression and long-term stability.
Every cultivar incorporated into our production programme is selected to support reproducibility, traceability and the quality requirements expected of regulated pharmaceutical products.
Our Cultivars
Selected for stability, phytochemical character and pharmaceutical suitability.
Our current genetic portfolio consists of carefully selected cultivars chosen for their stability, phytochemical characteristics and suitability for pharmaceutical production.
Each cultivar is continuously evaluated throughout cultivation and manufacturing to ensure it consistently meets the quality standards required for the production of pharmaceutical-grade cannabinoid medicines.
While each cultivar possesses unique cannabinoid and terpene characteristics, all are selected according to the same scientific principles: consistency, reproducibility, traceability and pharmaceutical quality.
MMB86 – M.Cocktail
- Terpene Profile
- Therapeutic Areas
- Chronic Pain, Spasticity, Chemotherapy-Induced Nausea, Loss of Appetite
- Origin
- California, USA
MMB89 – Gush Mints 1:1
- Terpene Profile
- Therapeutic Areas
- Chronic Pain, Spasticity, Chemotherapy-Induced Nausea, Loss of Appetite
- Origin
- California, USA
MMB45 – Fortyfive
- Terpene Profile
- Therapeutic Areas
- Chronic Pain, Spasticity, Chemotherapy-Induced Nausea, Loss of Appetite
- Origin
- California, USA
Disclaimer: Approved indications for medical cannabis products may vary by country and are subject to applicable local laws, regulations, and marketing authorizations.
Selection criteria
Evaluated scientifically, agronomically and pharmaceutically.
Every cultivar is evaluated against multiple criteria before being introduced into commercial production.
Genetic Stability
Maintaining consistent inherited characteristics throughout propagation and successive cultivation cycles.
Uniform Plant Performance
Promoting predictable growth behaviour, flowering characteristics and biomass production under controlled cultivation conditions.
Consistent Phytochemical Profiles
Supporting reproducible cannabinoid and terpene composition that contributes to standardized pharmaceutical manufacturing.
Agronomic Performance
Selecting cultivars demonstrating reliable cultivation performance, resilience and suitability for large-scale production.
Controlled Environment Adaptation
Prioritising genetics that perform consistently within standardized greenhouse and indoor cultivation environments.
Pharmaceutical Compatibility
Ensuring suitability for validated manufacturing processes, quality systems and regulatory expectations governing pharmaceutical production.
Looking ahead
Genetic stewardship continues to evolve.
The science of cannabinoid genetics continues to evolve, providing new insights into plant biology, phytochemistry and pharmaceutical development.
As our understanding advances, so too will our genetic portfolio.
Curity Pharma remains committed to the continuous evaluation and responsible selection of cultivars that support the development of increasingly consistent, reliable and high-quality cannabinoid medicines.
By combining genetic stewardship with pharmaceutical science, we aim to ensure that every generation of cultivars contributes to the advancement of cannabinoid therapeutics and the delivery of medicines that healthcare professionals can trust and patients can rely upon.